Psychedelics have become one of the most promising classes of drugs in a generation, as well as an exciting new industry for investors. Despite their resurgence among researchers and investors, psychedelics have been used for thousands of years before they were criminalized in the 1970s in the United States and around the world.
Let’s take a look at the rich history of psychedelics over thousands of years, the renaissance that has emerged over the past few years and how Tryp Therapeutics (CSE: TRYP, OTCQB: TRYPF) is positioning itself to unlock value through its PFN™ platform and recent patent filings.
A Brief History of Psychedelics
Psychedelics have a long history that began as early as 4,000 B.C. E. where cave paintings were found in Northern Africa and Europe. In 3,700 to 3,660 B.C.E., there’s evidence that peyote was used in ceremonies by indigenous cultures in the Americas. The Aztec’s may have consumed mushrooms, known as the “flash of the Gods” between 1300 and 1521 C.E. while Catholic texts from Europe in 1500 C.E. refer to peyote use as “witchcraft”.
Modern science began in the 1900s with the isolation of mescaline and ibogaine in Europe. Synthetics emerged soon after with the invention of MDMA in 1912 and LSD in 1938. Psilocybin was discovered by Albert Hoffman in 1958 and Calvin Stevens synthesized ketamine in 1962, which ushered in the modern era of psychedelics. Of course, these drugs were regulated around the world between 1962 and 1971, creating a prohibition era.
The psychedelic renaissance began after 1971 as researchers began to discover the potential for psychedelics to treat a range of different medical conditions. After widespread cannabis legalization in the early 2010s, the movement to decriminalize psychedelics—especially for research and medical use—picked up steam. The emergence of funding from venture capital investors helped finance large-scale clinical trials that finally tipped the scale in the 2020s.
Click here to learn more about investing in Tryp Therapeutics
Bringing Psychedelics to Medicine
A growing number of private and public companies have emerged in the late 2010s and early 2020s to develop and commercialize psychedelic treatments for medical conditions. In particular, psychiatric conditions like major depressive disorder and anxiety seem to be greatly enhanced through psychedelic treatments. The breakthroughs have been strong enough to secure Breakthrough Therapy Status for several programs from the U.S. FDA.
Tryp Therapeutics (CSE: TRYP, OTCQB:TRYPF) is a pharmaceutical company with a psilocybin-for-neuropsychiatric disorders, or PFN™, platform. By developing novel synthetic psilocybin, the company aims to power a new class of drugs for the treatment of certain neuropsychiatric disorders. The company’s lead PFN™ drug candidate is TRP-8802 for the treatment of fibromyalgia, a chronic pain syndrome with few effective treatments and no cure, and of eating disorders.
The company recently announced that it submitted a provisional patent to improve how psychedelics are administered across a broad range of conditions. In particular, the proprietary methods represent the foundational elements of a comprehensive medical treatment program that the company is developing. It also marks the first of many patent filings to enhance the effectiveness of psychedelics and build a valuable patent portfolio.
Click here to learn more about investing in Tryp Therapeutics
Looking Ahead
Psychedelics have a rich history spanning thousands of years. While the class of drugs has been restricted for therapeutic use since the 1970s, the psychedelic renaissance has sparked renewed interest and a range of companies seeking to bring therapeutics to market.
Tryp Therapeutics (CSE: TRYP) represents one of the most promising companies in the space with its PFN™ platform and its clinical research programs for fibromyalgia and eating disorders. With its recent provisional patent filing, the company is making core improvements to the formulation, delivery and dosing of active ingredients, helping to differentiate itself from other companies in the space. Investors may want to take a closer look at the stock given these dynamics and its upcoming clinical catalysts.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
